Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: A prospective study

European Journal of Dermatology

Volumn 27, Issue 3, 2017, Pages 266-270

  Dika, Emi ^a   Ravaioli, Giulia Maria ^a   Fanti, Pier Alessandro ^a   Piraccini, Bianca Maria ^a   Lambertini, Martina ^a   Chessa, Marco Adriano ^a   Baraldi, Carlotta ^a   Ribero, Simone ^b   Andrea, Ardizzoni ^a   Melotti, Barbara ^a   Patrizi, Annalisa ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Adverse events; Ipilimumab; Melanoma; Treatment

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CERAMIDE; CETIRIZINE; ERYTHROMYCIN; FLUCONAZOLE; FUSIDIC ACID; IPILIMUMAB; METHYLPREDNISOLONE; METRONIDAZOLE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ACNE; ARTICLE; CLINICAL ARTICLE; ECZEMA; EPILUMINESCENCE MICROSCOPY; FOLLICULITIS; HUMAN; METASTATIC MELANOMA; MUCOSA INFLAMMATION; NUMERIC RATING SCALE; PATIENT-REPORTED OUTCOME; PROSPECTIVE STUDY; PRURITUS; QUESTIONNAIRE; RASH; ROSACEA; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; VITILIGO; XEROSIS; CHEMICALLY INDUCED; DRUG ERUPTION; MELANOMA; METASTASIS; PATHOLOGY; SKIN TUMOR;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; DRUG ERUPTIONS; HUMANS; IPILIMUMAB; MELANOMA; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; PRURITUS; SKIN NEOPLASMS;

EID: 85021876798     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2017.3023     Document Type: Article

References (19)

1. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26: 2375.
2. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27: 559.
3. Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol 2012; 67: 1025-39.
4. Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs 2005; 14: 798-804.
5. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 190-209.
6. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691.
7. Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 2014; 71: 161.
8. Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2013; 69: e121-8.
9. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016; 44: 51-60.
10. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34.
11. Ludlow SP, Kay N. Delayed dermatologic hypersensitivity reaction secondary to ipilimumab. J Immunother 2015; 38: 165-6.
12. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-32.
13. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-30.
14. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375-84.
15. Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016; 152: 45-51.
16. Klein O, Ebert LM, Nicholaou T, et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 2009; 15: 2507-13.
17. Pintova S, Sidhu H, Friedlander PA, Holcombe RF. Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res 2013; 23: 498.
18. Abdel-Rahman O, ElHalawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol 2015; 11: 2471-84.
19. Dick J, Lang N, Slynko A, et al. Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. Immunotherapy 2016; 8: 1033-44.